

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



山東威高集團醫用高分子製品股份有限公司

Shandong Weigao Group Medical Polymer Company Limited *

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1066)

**(1) PROPOSED AMENDMENTS TO THE ARTICLES
OF ASSOCIATION
AND
(2) PROPOSED IMPLEMENTATION OF
H SHARE FULL CIRCULATION**

This announcement is made by the Company pursuant to Rule 13.09(2)(a) and Rule 13.51(1) of the Listing Rules and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION

The Board proposes to amend the Articles of Association to, among other things, (i) bring the existing Articles of Association in line with the Company Law which took effect from 1 July 2024 and provisions under the Guidelines for the Articles of Association of Listed Companies (《上市公司章程指引》) issued by the CSRC on 28 March 2025, and other relevant laws, regulations, rules and normative documents; (ii) provide the Company with flexibility to purchase or acquire shares to be held as treasury shares, in view of the amendments to the Listing Rules relating to treasury shares which took effect on 11 June 2024; (iii) align with the recent amendments to the Listing Rules in relation to the further expansion of paperless listing regime, which require issuers to ensure that their constitutional documents allow them to hold hybrid shareholders' meetings and provide electronic voting; (iv) make other consequential and house-keeping amendments in relation to items (i) to (iii) above; and (v) reflect the change in share capital structure of the Company following completion of the H Share Full Circulation and to make the relevant consequential and house-keeping amendments (collectively, the **"Proposed Amendments"**). The Board is of the view that the Proposed Amendments are in the interests of the Company and the Shareholders as a whole.

* For identification purpose only

The Proposed Amendments (except for the Proposed Amendments in relation to item (v)) set out in items (i) to (iv) are subject to the approval by the Shareholders by way of a special resolution at the EGM. The Articles of Association incorporating the aforesaid Proposed Amendments (except for the Proposed Amendments in relation to item (v)) will take effect upon conclusion of the EGM, subject to the approval by Shareholders at the EGM.

The Proposed Amendments in relation to item (v) are subject to (a) the approval by the Shareholders by way of a special resolution at the EGM; (b) the approval from, and registration and filing with the relevant government authorities of the PRC; and (c) completion of the H Share Full Circulation. Therefore, the Articles of Association incorporating the Proposed Amendments in relation to item (v) will take effect upon the latest of the conclusion of the EGM, the registration and filing with the relevant PRC authority, and completion of the H Share Full Circulation.

PROPOSED H SHARE FULL CIRCULATION

Reference is made to the Guidelines on Application for “Full Circulation” of Domestic Unlisted Shares of H-share Companies (《H股公司境內未上市股份申請“全流通”業務指引》) issued by the CSRC on 14 November 2019 and further amended on August 10, 2023 (the “**Guidelines**”), and the Trial Administrative Measures of Overseas Securities Offering and Listing by Domestic Companies (《境內企業境外發行證券和上市管理試行辦法》) issued by the CSRC on 17 February 2023 regarding the procedures to apply for full circulation of shares by companies whose H shares are listed on the Stock Exchange.

In view of the Guidelines, the Board considered and approved the proposed H Share Full Circulation in relation to 48,300,000 Unlisted Shares, representing approximately 1.06% of the total issued Shares as at the date of this announcement, held by certain Shareholders. Subject to obtaining all relevant approvals (including the filing notice by the CSRC and the approval of the Stock Exchange) and compliance with all applicable laws, rules and regulations, such 48,300,000 Unlisted Shares will be converted into H Shares. The Company will apply to the Stock Exchange for the listing of, and permission to deal in, such H Shares on the Main Board of the Stock Exchange.

Pursuant to the Articles of Association, no approval from the Shareholders will be required for the proposed H Share Full Circulation.

The proposed H Share Full Circulation is subject to the fulfilment of the following conditions:

- (1) the approval of the proposed H Share Full Circulation by CSRC having been obtained; and
- (2) the Listing Committee of the Stock Exchange having granted the listing of, and permission to deal in, the H Shares converted from Unlisted Shares through the H Share Full Circulation.

As at the date of this announcement, none of the aforesaid conditions has been satisfied. The Company will make further announcement(s) on the progress of the H Share Full Circulation in accordance with the requirements of the Listing Rules and other applicable laws and regulations as and when necessary and appropriate.

EGM

The Company will convene and hold the EGM for the Shareholders to consider and, if thought fit, approve (among others) the Proposed Amendments and the related authorization.

A circular containing, among other matters, details of the Proposed Amendments and the related authorisation, together with the notice of the EGM, will be despatched to the Shareholders in due course.

As the proposed H Share Full Circulation is subject to certain conditions and other relevant procedures as required by the CSRC and the Stock Exchange, Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

DEFINITIONS

In this announcement, the following expressions shall have the following meanings unless the context otherwise requires.

“Articles of Association”	the articles of association of the Company as amended from time to time
“Board”	the board of Directors
“Company”	Shandong Weigao Group Medical Polymer Company Limited* (山東威高集團醫用高分子製品股份有限公司), a joint stock limited company incorporated in the PRC with limited liability and the H Shares of which are listed on the Main Board of the Stock Exchange (stock code: 1066)
“CSRC”	the China Securities Regulatory Commission (中國證券監督管理委員會)
“Director(s)”	director(s) of the Company
“EGM”	the extraordinary general meeting of the Company to be convened and held to consider, and if thought fit, approve (among others), the Proposed Amendments
“H Share(s)”	the overseas-listed foreign invested shares in the share capital of the Company, with a nominal value of RMB0.10 each, which are held and traded in Hong Kong dollars

“H Share Full Circulation”	the proposed conversion of 48,300,000 Unlisted Shares held by the Participating Shareholders into H Shares and the listing of such H Shares on the Main Board of the Stock Exchange
“Hong Kong”	the Hong Kong Special Administrative Region of the PRC
“Listing Rules”	the Rules Governing the Listing of Securities on the Stock Exchange
“Participating Shareholder(s)”	holder(s) of Unlisted Share(s) who participate(s) in the proposed H Share Full Circulation
“PRC”	the People’s Republic of China
“RMB”	Renminbi, the lawful currency of the PRC
“Shares”	issued shares of the Company, which comprise both Unlisted Shares and H Shares
“Shareholder(s)”	holder(s) of Share(s)
“Stock Exchange”	The Stock Exchange of Hong Kong Limited
“treasury share(s)”	has the meaning ascribed to it under the Listing Rules

“Unlisted Share(s)” ordinary share(s) in the share capital of the Company, with a nominal value of RMB0.10 each, which are not listed or traded on any stock exchange

“%” per cent.

By order of the Board
Shandong Weigao Group Medical Polymer Company Limited
Long Jing
Chairman

Weihai, Shandong, the PRC, 29 September 2025

As at the date of this announcement, the Board comprises:

Mr. Long Jing (*Executive Director*)
Mr. Cong Rinan (*Executive Director*)
Mr. Lu Junqiang (*Executive Director*)
Mr. Wang Daoming (*Executive Director*)
Ms. Yan Xia (*Non-executive Director*)
Mr. Chen Lin (*Non-executive Director*)
Mr. Tang Zhengpeng (*Non-executive Director*)
Mr. Li Guohui (*Independent Non-executive Director*)
Mrs. Meng Hong (*Independent Non-executive Director*)
Mr. Li Qiang (*Independent Non-executive Director*)
Mr. Sun Heng (*Independent Non-executive Director*)